Rate My Professor Sukhwinder Shergill

Shergill’s research employs neuroimaging techniques to investigate brain functions and structures underlying schizophrenia, focusing on positive symptoms such as hallucinations and paranoia, as well as cognitive and negative symptoms like memory, attention, and social interaction deficits. He extends this expertise to other psychiatric illnesses and leads commercial clinical trials with pharmaceutical companies including Boehringer Ingelheim, Takeda, Roche, and GlaxoSmithKline. He has authored over 250 peer-reviewed publications, including highly cited works such as 'Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging' (Archives of General Psychiatry, 2000, 906 citations), 'Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials' (Schizophrenia Bulletin, 2015, 881 citations), and 'Evidence for sensory prediction deficits in schizophrenia' (American Journal of Psychiatry, 2005, 541 citations). His contributions have earned awards including Psychiatric Academic Researcher of the Year from the Royal College of Psychiatrists (2015), Innovative Teacher of the Year at King’s College London (2009), and the Association of European Psychiatrists Research Prize (2002). Shergill serves on the editorial board of the British Journal of Psychiatry since 2004, holds multiple committee roles such as member of the Wellcome Trust Career Development Awards Interview Committee, and engages in public outreach through campaigns like Better Health – Every Mind Matters and artistic collaborations.